Concomitant febuxostat enhances methotrexate-induced hepatotoxicity by inhibiting breast cancer resistance protein

Methotrexate (MTX) is an antifolate agent used for the treatment of various malignancies and is eliminated by breast cancer resistance protein (BCRP). Because febuxostat (FBX) is known to inhibit BCRP activity, FBX might exacerbate MTX-related adverse effects. In this study, we examined the drug-dru...

Descripción completa

Detalles Bibliográficos
Autores principales: Ikemura, Kenji, Hiramatsu, Shun-ichi, Shinogi, Yuri, Nakatani, Yusuke, Tawara, Isao, Iwamoto, Takuya, Katayama, Naoyuki, Okuda, Masahiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6937279/
https://www.ncbi.nlm.nih.gov/pubmed/31889141
http://dx.doi.org/10.1038/s41598-019-56900-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6937279/
https://www.ncbi.nlm.nih.gov/pubmed/31889141
http://dx.doi.org/10.1038/s41598-019-56900-2

Ejemplares similares